Alkermes (ALKS) stock forecast for 2022
Last update: May 29, 2023 (12:33)Sector: Healthcare
The share price of Alkermes plc (ALKS) now
50/200 Day Moving Average: $29.01 / $26.09
This figure corresponds to the Average Price over the previous 50/200 days. For Alkermes stocks, the 50-day moving average is the resistance level today.
For Alkermes stocks, the 200-day moving average is the resistance level today.
Are you interested in Alkermes stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Alkermes stock price in 2022. How much will one Alkermes share be worth in 2022? Is it worth taking profit / loss on Alkermes stock now or waiting? What are analysts' forecasts for Alkermes stock?
We forecast Alkermes stock performance using neural networks based on historical data on Alkermes stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. The Alkermes stock prediction results are shown below and presented as a graph, table and text information.
Alkermes stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Alkermes analysts is $35.33.
Today 200 Day Moving Average is the support level (26.09 $).
50 Day Moving Average is the support level (29.01 $).
Historical and forecast chart of Alkermes stock
The chart below shows the historical price of Alkermes stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Alkermes stock price can be found in the table below.
Alkermes (ALKS) Forecast for 2022
Alkermes information and performance
Alkermes plc is an Irish biopharmaceutical company that researches, develops and markets pharmaceutical products used in a variety of therapeutic areas around the world. The company’s products include drugs for the treatment of schizophrenia, schizoaffective, depressive and bipolar disorder, alcohol and opioid addiction, aids to improve walking in adults with multiple sclerosis, and a drug for the treatment of type 2 diabetes. The company serves pharmaceutical wholesalers, specialized pharmacies and distributors.
CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, IE
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Alkermes price target for 2022 by month
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.